Compare BioNTech SE - ADR (BNTX) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Five Below Inc — how do they compare? BioNTech SE - ADR trades at $90.08 (market cap $22.86B), while Five Below Inc trades at $194.97 (market cap $10.68B). The key difference: BioNTech SE - ADR is far larger — about 2.1× Five Below Inc's market cap, and Five Below Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | FIVE | |
|---|---|---|
Market Cap | $22.86B | $10.68B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $247.71 |
52-Week Low | $83.89 | $131.94 |
Enterprise Value | $6.53B | $11.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Five Below (FIVE) trades at $191.53, up 1.13% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 21.13% ROE and 8.67% net margin, supported by revenue growth from $3.6B in 2024 to $3.9B in 2025. Recent milestones include opening its 2,000th store and leadership appointments, driving positive media coverage.
The outlook remains positive with a $252.09 analyst price target implying 31% upside, though risks include volatile cash flows and competitive pressures. Earnings momentum and digital marketing investments position FIVE for growth, but investors should monitor execution against 2026's $5.1B revenue target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
